GAITHERSBURG, Md.–(BUSINESS WIRE)–GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the third quarter of 2026 after the market closes on Monday, November 9, 2026. Management will host a conference call that day to discuss third quarter 2026 financial and operating results at 4:30 p.m. Eastern Time. Conference Call Details Investors interested in listening to the conference ca